
Impacted by higher tax outgo, pharma major Aurobindo Pharma’s posted a 12% drop in consolidated net profit for the fourth quarter ended March 31, 2023, at Rs 506 crore as compared to Rs 576 crore in the corresponding quarter of financial year 2021-22. https://ift.tt/yPN18cp
Post Comment
No comments
PLEASE DO NOT ENTER ANY SPAM LINK IN THE COMMENT BOX